# Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

> **NCT05462717** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Revolution Medicines, Inc.** · enrollment: 222 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** RMC-6291

## Key facts

- **NCT ID:** NCT05462717
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-19
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462717, "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05462717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*